Stacy Loeb1, Ashley E Ross. 1. aDepartment of Urology and Population Health, New York University, and the Manhattan VA Medical Center, New York, New York bBrady Urological Institute, Johns Hopkins Medical Institutes, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: The goal of this article is to discuss current genomic testing options in localized prostate cancer. RECENT FINDINGS: There are multiple genomic tests currently available for men with localized prostate cancer. Prolaris, OncotypeDx, and Decipher can all be tested using biopsy tissue. Prolaris and Decipher are also available for men undergoing radical prostatectomy to predict subsequent disease progression. SUMMARY: The Prolaris cell cycle progression score measured on biopsy predicts the risk of prostate cancer death in 10 years with conservative management, whereas, the primary endpoint for the OncotypeDx genomic prostate score is the risk of adverse disease at radical prostatectomy. Decipher measures genome-wide RNA expression, and its Genomic Classifier signature was initially designed to predict the risk of metastasis for men with adverse disease at radical prostatectomy, and more recently, a biopsy version was released. Recently, Decipher signatures predicting prostate cancer cell lineage and postoperative radiation sensitivity have also been described. Any of these tests can be used by men with localized prostate cancer to provide additional prognostic risk stratification to aid in treatment decisions.
PURPOSE OF REVIEW: The goal of this article is to discuss current genomic testing options in localized prostate cancer. RECENT FINDINGS: There are multiple genomic tests currently available for men with localized prostate cancer. Prolaris, OncotypeDx, and Decipher can all be tested using biopsy tissue. Prolaris and Decipher are also available for men undergoing radical prostatectomy to predict subsequent disease progression. SUMMARY: The Prolaris cell cycle progression score measured on biopsy predicts the risk of prostate cancer death in 10 years with conservative management, whereas, the primary endpoint for the OncotypeDx genomic prostate score is the risk of adverse disease at radical prostatectomy. Decipher measures genome-wide RNA expression, and its Genomic Classifier signature was initially designed to predict the risk of metastasis for men with adverse disease at radical prostatectomy, and more recently, a biopsy version was released. Recently, Decipher signatures predicting prostate cancer cell lineage and postoperative radiation sensitivity have also been described. Any of these tests can be used by men with localized prostate cancer to provide additional prognostic risk stratification to aid in treatment decisions.
Authors: Ashley E Ross; Michael H Johnson; Kasra Yousefi; Elai Davicioni; George J Netto; Luigi Marchionni; Helen L Fedor; Stephanie Glavaris; Voleak Choeurng; Christine Buerki; Nicholas Erho; Lucia L Lam; Elizabeth B Humphreys; Sheila Faraj; Stephania M Bezerra; Misop Han; Alan W Partin; Bruce J Trock; Edward M Schaeffer Journal: Eur Urol Date: 2015-06-06 Impact factor: 20.096
Authors: Deepansh Dalela; María Santiago-Jiménez; Kasra Yousefi; R Jeffrey Karnes; Ashley E Ross; Robert B Den; Stephen J Freedland; Edward M Schaeffer; Adam P Dicker; Mani Menon; Alberto Briganti; Elai Davicioni; Firas Abdollah Journal: J Clin Oncol Date: 2017-03-28 Impact factor: 44.544
Authors: E David Crawford; Mark C Scholz; Ashok J Kar; Jeffrey E Fegan; Abebe Haregewoin; Rajesh R Kaldate; Michael K Brawer Journal: Curr Med Res Opin Date: 2014-03-13 Impact factor: 2.580
Authors: Matthew R Cooperberg; Elai Davicioni; Anamaria Crisan; Robert B Jenkins; Mercedeh Ghadessi; R Jeffrey Karnes Journal: Eur Urol Date: 2014-07-02 Impact factor: 20.096
Authors: R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins Journal: J Urol Date: 2013-06-11 Impact factor: 7.450
Authors: Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Nicholas Erho; Anamaria Crisan; Ismael A Vergara; Anirban P Mitra; Mercedeh Ghadessi; Christine Buerki; Eric J Bergstralh; Thomas Kollmeyer; Stephanie Fink; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Karla V Ballman; Timothy J Triche; Peter C Black; R Jeffrey Karnes; George Klee; Elai Davicioni; Robert B Jenkins Journal: PLoS One Date: 2013-06-24 Impact factor: 3.240
Authors: J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone Journal: Br J Cancer Date: 2012-02-23 Impact factor: 7.640
Authors: Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian Journal: Nat Rev Urol Date: 2020-12-16 Impact factor: 14.432
Authors: Peter K F Chiu; Eric K C Lee; Marco T Y Chan; Wilson H C Chan; M H Cheung; Martin H C Lam; Edmond S K Ma; Darren M C Poon Journal: Front Oncol Date: 2022-07-18 Impact factor: 5.738